What was Innate Pharma SA’s price range in the past 12 months?
Innate Pharma SA lowest stock price was €1.33 and its highest was €2.50 in the past 12 months.
What is Innate Pharma SA’s market cap?
Innate Pharma SA’s market cap is €150.42M.
When is Innate Pharma SA’s upcoming earnings report date?
Innate Pharma SA’s upcoming earnings report date is Mar 19, 2026 which is in 94 days.
How were Innate Pharma SA’s earnings last quarter?
Innate Pharma SA released its earnings results on Sep 17, 2025. The company reported -€0.25 earnings per share for the quarter, beating the consensus estimate of -€0.28 by €0.03.
Innate Pharma SA does not currently pay dividends.
What is Innate Pharma SA’s EPS estimate?
Innate Pharma SA’s EPS estimate is -0.12.
How many shares outstanding does Innate Pharma SA have?
Innate Pharma SA has 92,189,370 shares outstanding.
What happened to Innate Pharma SA’s price movement after its last earnings report?
Innate Pharma SA reported an EPS of -€0.25 in its last earnings report, beating expectations of -€0.28. Following the earnings report the stock price went down -1.784%.
Which hedge fund is a major shareholder of Innate Pharma SA?
Currently, no hedge funds are holding shares in FR:IPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Innate Pharma SA
Innate Pharma SA (IPH) is a biotechnology company based in France that specializes in the development of innovative immunotherapy treatments for cancer. The company focuses on harnessing the immune system to fight cancer through its proprietary antibody technology, particularly in the development of monoclonal antibodies and other therapeutic agents targeting various cancer indications. Innate Pharma aims to provide breakthrough therapies that improve patient outcomes in oncology.
The earnings call reflected a strategic shift towards prioritizing high-value clinical assets with promising progress in key trials. However, there were concerns over reduced R&D spending and the deprioritization of certain research areas, alongside the departure of a key scientific leader. The company's financial position remains stable, providing support for its strategic objectives.View all FR:IPH earnings summaries